Home | General Information | E-Resources | E-Consultation | E-Learning | Site Map | ORBIS | Feedback
Home > E-Resources Home > QUESTION OF THE WEEK Home > Answers: 2010 Series Home > April 6, 2010
QUESTION OF THE WEEK
VIDEO LIBRARY
OPHTHALMOLOGY BOOKS & MANUALS
Nursing Education
Clinical Challenges
The Ophthalmology Minute
Eye Care Equipment
Ask a Professor
mLearning
ORBIS Program Features
FREE ONLINE JOURNALS
OPHTHALMOLOGY LINKS
I Have a Question
Print ViewPrint this Page
Answers: 2010 Series -  April 6, 2010 Lecture 39 of 52  NEXT»

To see views enlarged, click on the individual pictures...

QOWpic1 QOWpic2 QOWpic3
Photos courtesy of: Bita Esmaeli, M.D. / M.D. Anderson Cancer Center
Used with permission. Not to be reproduced.

A 57-year-female presented with painless right lacrimal fossa fullness and diplopia. MRI and histology of a touch prep and permanent section of an incisional biopsy specimen are shown.

1. This represents:

e -- the most common primary orbital malignancy in adults

This patient had MALT orbital lymphoma. The MRI shows a well circumscribed orbital mass that molds to orbital structures without bony destruction. The touch prep identifies abnormal appearing lymphocytes, and the permanent section slide confirms lymphoma showing a monotonous population of lymphocytes. Orbital lymphoma is the most common primary orbital malignancy in adults, however it is a lymphoproliferative (and not epithelial) tumor.

2. The next step in the care of this patient should be:

e -- systemic evaluation of involvement of other sites

All ocular adnexal and orbital lymphoproliferative lesions warrant systemic evaluation to investigate other potential anatomic sites involved prior to treatment considerations. Work-up may include head and neck imaging through CT or MRI, neck ultrasound, CT of the chest/abdomen/pelvis, whole body PET CT, bone marrow biopsy, and when warranted upper endoscopy.

3. If the patient’s disease is localized to the orbit, treatment may be:

d -- radiotherapy

Treatment of orbital lymphoma may include radiotherapy, chemotherapy, or radioimmunotherapy (Rituximab) or a combination thereof.   

 


Lecture 39 of 52 «Previous Lecture   1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52    Next»